New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:04 EDTDPRXDipexium Pharmaceuticals begins Phase 3 clinical trial of Locilex for foot ulcer
Dipexium Pharmaceuticals has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials evaluating Locilex, the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The FDA has agreed to a Special Protocol Assessment with Dipexium for Locilex's pivotal Phase 3 clinical trial program in Mild DFI.
News For DPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:08 EDTDPRXDipexium Pharmaceuticals passes 25% enrollment in Locilex Phase 3 trials
Subscribe for More Information
February 17, 2015
08:06 EDTDPRXDipexium Pharmaceuticals reports positive results from phase DPX-120 trial
Dipexium Pharmaceuticals announced successful completion and initial results of DPX-120, a Phase 1 skin sensitization trial of Locilex, the Company's novel, broad-spectrum topical antibiotic peptide. DPX-120 was a single-center, double-blind study in healthy adult subjects with the primary objective of evaluating the potential of Locilex and its vehicle cream to induce contact sensitization by repetitive application to human skin. Volunteers received applications of Locilex, vehicle cream, and a low irritant control 3 times each week for 3 weeks during an induction phase, followed by 2 weeks without dosing and then a single challenge dose to intact skin. Visual skin irritation assessments were performed by trained and blinded evaluators using a well-established, FDA-recognized standardized rating scale.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use